Xcovery is a clinical-stage company focused on the development of next generation targeted therapeutics for cancer. The company is leveraging the combined entrepreneurial and scientific successes of its two founders, Sheridan G. Snyder and Chris Liang, PhD, to become one of the most significant independent developers of small molecule kinase inhibitors. The Xcovery portfolio consists of six novel low toxicity drug candidates making them ideal components for combination therapy, the future of molecular targeted therapy in cancer.